Indivior PLC

Indivior and Supernus Pharmaceuticals announced a merger of equals to create a diversified CNS biopharmaceutical leader with significant scale and an expanded portfolio of 11 medicines.

Indivior Pharmaceuticals announced robust second-quarter 2026 financial results, exceeding expectations with significant year-over-year growth in revenue and profitability, leading to an upward revision of its full-year financial outlook.

Indivior Pharmaceuticals and Supernus Pharmaceuticals announced a definitive agreement to merge, creating a diversified CNS biopharmaceutical company with combined annual revenues of approximately $2.2 billion.

Indivior Pharmaceuticals reports the elimination of its Chief Scientific Officer role and confirms the successful re-election of its board and auditor ratification.

Indivior Pharmaceuticals, Inc. has entered into an accelerated share repurchase agreement to buy back $175 million of its common stock.

Indivior Pharmaceuticals announced robust first-quarter 2026 financial results, driven by significant SUBLOCADE revenue growth, and consequently raised its full-year 2026 financial guidance.

Indivior Pharmaceuticals announced robust Q2 2026 financial results with a 14% revenue increase, driven by SUBLOCADE, and significant progress on its merger with Supernus Pharmaceuticals.

Indivior PLC reported a significant increase in net income for Q3 2025, driven by strong SUBLOCADE sales and ongoing strategic restructuring initiatives.

Indivior PLC reported a significant turnaround to net income in the second quarter of 2025, driven by robust SUBLOCADE sales and improved gross margins, despite ongoing litigation challenges and a one-time UK tax settlement.

Indivior PLC's Q1 2025 net revenue decreased by 6% year-over-year to $266 million, primarily due to increased competition affecting SUBOXONE Film sales in the U.S.

Indivior Pharmaceuticals reports strong 2025 revenue growth driven by SUBLOCADE, alongside strategic restructuring and U.S. domestication.

Indivior PLC's 2024 10-K filing highlights its focus on substance use disorder treatments, particularly SUBLOCADE, while addressing ongoing litigation, competitive pressures, and regulatory compliance.

Indivior and Supernus Pharmaceuticals announce an all-stock merger of equals to create a leading U.S. biopharmaceutical company focused on central nervous system diseases.

Indivior Pharmaceuticals and Supernus Pharmaceuticals announced a merger of equals to create a diversified CNS biopharmaceutical company with significant scale and projected annual cost synergies of at least $125 million.

Indivior Pharmaceuticals announced robust second quarter 2026 financial results, exceeding expectations and leading to an upward revision of full-year guidance, alongside progress on its merger with Supernus.

Indivior Pharmaceuticals and Supernus Pharmaceuticals announce a merger of equals, creating a diversified CNS biopharmaceutical company named Supernus, Inc.

Christian Heidbreder, Chief Scientific Officer of Indivior Plc, sold 18,586 shares of common stock on July 10, 2026 for $41.14 per share.

Chief Scientific Officer Christian Heidbreder sold 18,586 shares of Indivior common stock via a Rule 10b5-1 trading plan.

Indivior Pharmaceuticals reports a successful 2025, marked by significant revenue growth, increased profitability, and strategic advancements in its U.S. SUBLOCADE business.

Oaktree Capital Management and its affiliates have significantly reduced their beneficial ownership in Indivior PLC, selling over 1.6 million shares in December 2025.

Two Seas Capital LP and its affiliates have reduced their beneficial ownership in Indivior PLC to 4.98%, falling below the 5% reporting threshold.

Two Seas Capital LP and its affiliates have reduced their beneficial ownership in Indivior PLC to 5.7% through a series of open market transactions.

Oaktree Capital Management and its affiliates have reduced their beneficial ownership in Indivior PLC to 7.0% through a series of share sales.

Two Seas Capital LP and affiliates updated their Schedule 13D filing for Indivior PLC, disclosing a 7.4% beneficial ownership and recent trading activity including significant share sales.

Two Seas Capital LP and affiliates filed an Amendment No. 10 to their Schedule 13D, reporting a beneficial ownership of 8.3% in Indivior PLC after significant share sales.

Madison Avenue International LP and affiliated entities report beneficial ownership of 4,315,162 shares, representing 3.5% of Indivior Pharmaceuticals' common stock as of March 31, 2026.

Fuller & Thaler Asset Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 4,529,583.47 shares of Indivior Pharmaceuticals, Inc. common stock, representing 3.72% of the class.

Vanguard Portfolio Management has reported beneficial ownership of 6.55% of Indivior Pharmaceuticals Inc.'s common stock as of March 31, 2026.

Vanguard Capital Management has filed a Schedule 13G reporting a 5.35% beneficial ownership stake in Indivior Pharmaceuticals Inc.

Millennium Management LLC and affiliates reported their beneficial ownership in Indivior Pharmaceuticals, Inc. common stock has fallen to 3.8%, ceasing to be a 5% beneficial owner.

Fuller & Thaler Asset Management, Inc. has reported a passive 5.10% ownership stake in Indivior Pharmaceuticals, Inc. as of December 31, 2025.